Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016
Published Jul 27, 2016
184 pages — Published Jul 27, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016, provides an overview of the Systemic Sclerosis (Scleroderma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
- The report reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Systemic Sclerosis (Scleroderma) therapeutics and enlists all their major and minor projects
- The report assesses Systemic Sclerosis (Scleroderma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8302IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables81
  List of Figures91
Introduction101
  Global Markets Direct Report Coverage101
Systemic Sclerosis (Scleroderma) Overview111
Therapeutics Development122
  Pipeline Products for Systemic Sclerosis (Scleroderma) Overview121
  Pipeline Products for Systemic Sclerosis (Scleroderma) Comparative Analysis131
Systemic Sclerosis (Scleroderma) Therapeutics under Development by Companies142
Systemic Sclerosis (Scleroderma) Therapeutics under Investigation by Universities/Institutes161
Systemic Sclerosis (Scleroderma) Pipeline Products Glance174
  Late Stage Products171
  Clinical Stage Products181
  Early Stage Products191
  Unknown Stage Products201
Systemic Sclerosis (Scleroderma) Products under Development by Companies212
Systemic Sclerosis (Scleroderma) Products under Investigation by Universities/Institutes231
Systemic Sclerosis (Scleroderma) Companies Involved in Therapeutics Development2431
  Allergan Plc241
  Angion Biomedica Corp.251
  Antitope Limited261
  Bayer AG271
  BioLineRx, Ltd.281
  BiOrion Technologies B.V.291
  Boehringer Ingelheim GmbH301
  Bristol-Myers Squibb Company311
  Covis Pharmaceuticals, Inc.321
  CSL Limited331
  Cumberland Pharmaceuticals, Inc.341
  Digna Biotech, S.L.351
  F. Hoffmann-La Roche Ltd.361
  Fibrocell Science, Inc.371
  GenKyoTex S.A.381
  Gilead Sciences, Inc.391
  GlaxoSmithKline Plc401
  iBio, Inc.411
  Inventiva421
  Kadmon Corporation, LLC431
  MedImmune, LLC441
  miRagen Therapeutics, Inc.451
  PDX Pharmaceuticals LLC461
  Peptinov SAS471
  ProMetic Life Sciences Inc.481
  Ribomic Inc.491
  Sanofi501
  Stemline Therapeutics, Inc.511
  Stratatech Corporation521
  Vida Therapeutics Inc.531
  VivaCell Biotechnology Espana S.L.541
Systemic Sclerosis (Scleroderma) Therapeutics Assessment5513
  Assessment by Monotherapy Products551
  Assessment by Target564
  Assessment by Mechanism of Action604
  Assessment by Route of Administration642
  Assessment by Molecule Type662
Drug Profiles68101
  abatacept Drug Profile685
  acALY-18 Drug Profile731
  acetylcysteine Drug Profile741
  ambrisentan Drug Profile752
  ANG-3070 Drug Profile771
  belimumab Drug Profile786
  BL-1110 Drug Profile841
  BOT-191 Drug Profile851
  C-1889 Drug Profile862
  C-82 Drug Profile881
  Cell Therapy for Dermatology and Immunology Drug Profile892
  CM-101 Drug Profile911
  disitertide Drug Profile922
  factor XIII (human) Drug Profile941
  FCX-013 Drug Profile951
  GKT-831 Drug Profile963
  GSK-2330811 Drug Profile991
  IBIOCFB-03 Drug Profile1002
  ifetroban sodium Drug Profile1022
  IVA-337 Drug Profile1041
  JBT-101 Drug Profile1055
  KD-025 Drug Profile1104
  M-10 Drug Profile1141
  MEDI-7734 Drug Profile1151
  MGN-4220 Drug Profile1161
  Monoclonal Antibodies to Inhibit IL-3RA for Autoimmune Disorders Drug Profile1171
  nintedanib Drug Profile11810
  nitroglycerin Drug Profile1282
  Oligonucleotide for Scleroderma Drug Profile1301
  onabotulinumtoxin A Drug Profile1315
  PAT-048 Drug Profile1361
  PBI-4050 Drug Profile1375
  PDX-002 Drug Profile1421
  PPV-06 Drug Profile1431
  RBM-006 Drug Profile1441
  riociguat Drug Profile1456
  RP-182 Drug Profile1511
  SAR-100842 Drug Profile1521
  SAR-317461 Drug Profile1531
  Small Molecule to Inhibit NFkB for Immunology and Oncology Drug Profile1541
  SRI-35241 Drug Profile1551
  Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis Drug Profile1561
  terguride Drug Profile1571
  tocilizumab Drug Profile1588
  VCE-0048 Drug Profile1661
  VEDA-1209 Drug Profile1671
  VTI-1000 Series Drug Profile1681
Systemic Sclerosis (Scleroderma) Dormant Projects1693
Systemic Sclerosis (Scleroderma) Discontinued Products1721
Systemic Sclerosis (Scleroderma) Product Development Milestones17310
  Featured News &Press Releases1731
    Jul 05, 2016: iBio, Inc. Receives FDA Orphan Drug Designation for Fibrosis Product Candidate1731
    Jun 29, 2016: Fibrocell Announces Update on FCX-0131731
    Jun 16, 2016: Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis1741
    Apr 27, 2016: Cumberland Pharmaceuticals Announces New Program To Develop Vasculan For Systemic Sclerosis1741
    Apr 25, 2016: Fibrocell Receives Orphan Drug Designation from the FDA for FCX-013 for the Treatment of Localized Scleroderma1751
    Apr 12, 2016: Corbus Pharmaceuticals Receives FDA Approval for Open-Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis1761
    Mar 17, 2016: Chugai receives Orphan Drug Designation for Tocilizumab in Systemic Scleroderma1771
    Mar 15, 2016: ProMetic announces the addition of scleroderma to PBI-4050 targeted indications1771
    Feb 25, 2016: Inventiva rewarded for its innovative approach with IVA337 at the 4th Systemic Sclerosis World Congress1781
    Jan 28, 2016: IVA337 delivers significant therapeutic advances in fibrosis, a major public health challenge1781
    Dec 08, 2015: New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis1791
    Nov 12, 2015: miRagen Therapeutics Initiates First Clinical Trial for Anti-Fibrosis Product Candidate MRG-2011801
    Nov 11, 2015: Genkyotex's GKT137831 Granted Orphan Drug Designation in the US and EU for the Treatment of Systemic Sclerosis1811
    Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum1811
    Oct 07, 2015: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab for Systemic Sclerosis1821
Appendix1832
  Methodology1831
  Coverage1831
  Secondary Research1831
  Primary Research1831
  Expert Panel Validation1831
  Contact Us1831
  Disclaimer1841

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016" Jul 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Systemic-Sclerosis-Scleroderma-Pipeline-Review-H2-2016-2088-16266>
  
APA:
Global Markets Direct - Market Research. (2016). Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2016 Jul 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Systemic-Sclerosis-Scleroderma-Pipeline-Review-H2-2016-2088-16266>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.